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Abstract
Purpose Initial dose of chemotherapy is planned based on body surface area, which does not take body composition into 
account. We studied the association between fat mass (kg and relative to total body weight) as well as lean mass (kg and rela-
tive to total body weight) and toxicity-induced modifications of treatment in breast cancer patients receiving chemotherapy.
Methods In an observational study among 172 breast cancer patients (stage I–IIIB) in the Netherlands, we assessed body 
composition using dual-energy X-ray scans. Information on toxicity-induced modifications of treatment, defined as dose 
reductions, cycle delays, regimen switches, or premature termination of chemotherapy, was abstracted from medical records. 
Adjusted hazard ratios and 95% confidence intervals (95% CI) were calculated to assess associations between body composi-
tion and the risk of toxicity-induced modifications of treatment.
Results In total, 95 out of 172 (55%) patients experienced toxicity-induced modifications of treatment. Higher absolute 
and relative fat mass were associated with higher risk of these modifications (HR 1.14 per 5 kg; 95% CI 1.04–1.25 and HR 
1.21 per 5%; 95% CI 1.05–1.38, respectively). A higher relative lean mass was associated with a lower risk of modifications 
(HR 0.83 per 5%; 95% CI 0.72–0.96). There was no association between absolute lean mass and risk of toxicity-induced 
modifications of treatment.
Conclusions A higher absolute and a higher relative fat mass was associated with an increased risk of toxicity-induced 
modifications of treatment. Absolute lean mass was not associated with risk of these treatment modifications, while higher 
relative lean mass associated with lower risk of modifications. These data suggest that total fat mass importantly determines 
the risk of toxicities during chemotherapy in breast cancer patients.
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Introduction
Breast cancer patients are often treated with chemother-
apy, which usually consist of a combination of anthra-
cyclines (e.g., doxorubicin, epirubicin) and taxanes (e.g., 
paclitaxel, docetaxel) with or without targeted therapy [1, 
2]. Severe side effects during chemotherapy can lead to a 
dose reduction, cycle delay, or premature termination of 
treatment. These toxicity-induced modifications of treat-
ment may eventually lead to a reduced dose intensity, and 
worse outcome [3].
In clinical practice, the administered dose of the chemo-
therapy is based on the body surface area. Body surface 
area is usually calculated using the Mosteller formula 
based on height and weight [4]. However, it does not dis-
tinguish lean mass from fat mass or other characteristics 
of body composition. It has been suggested that body com-
position may be more important than body surface area for 
calculating the administered dose of chemotherapy, since 
previous studies in other cancer types showed that patients 
with low lean mass have a higher risk of toxicities as a 
result of treatment [5–9].
In patients with metastatic breast cancer, sarcopenia as 
well as low muscle mass or low lean mass were associ-
ated with increased risk of toxicities during chemotherapy 
[10–12]. Body composition of metastatic breast cancer 
patients generally differs from early stage breast cancer 
patients, because of disease-related sarcopenia and/or 
cachexia. Therefore, findings in metastatic breast cancer may 
not be generalizable to early stage breast cancer [10, 12, 13].
So far, only two studies on body composition in associa-
tion with treatment-related toxicities in early breast can-
cer patients were published. Both studies suggested that a 
lower lean mass was associated with an increased risk of 
toxicities [14, 15].
The goal of this paper was to focus not only on lean 
mass, but also to study associations between fat mass and 
risk of toxicities. Thus, we aimed to assess the associa-
tion between fat mass, lean mass, and the risk of toxic-
ity-induced modifications of treatment [16] in women 
with stage I-IIIB breast cancer receiving (neo)adjuvant 
chemotherapy.
Methods
Participants
This study is part of the COBRA-study, an observational 
multi-centre study among breast cancer patients receiv-
ing (neo)adjuvant chemotherapy [17]. Eligible patients 
were recruited by the medical staff from 11 academic and 
peripheral hospitals in the Netherlands prior to commence-
ment of chemotherapy. Women were eligible if they were 
newly diagnosed with operable stage I–IIIB breast cancer, 
and scheduled to receive (neo)adjuvant chemotherapy. Par-
ticipants needed to be at least 18 years old and be able to 
communicate in Dutch. Exclusion criteria were history of 
cancer, previous treatment with chemotherapy, (intended) 
pregnancy during the study period, dementia, or other 
mental conditions that made it impossible to comply with 
the study procedures.
For the current analyses, data were available for 176 
breast cancer patients recruited between May 2013 and Sep-
tember 2016. Four patients had to be excluded, because they 
had no dual-energy X-ray absorption (DEXA)-scan avail-
able. In total, we considered 172 patients for the analyses 
for this study.
The study protocol was approved by the Medical Ethical 
Committee of Wageningen University & Research, the Neth-
erlands. All participants provided written informed consent.
Data collection
Body composition
Body composition was assessed using a dual energy X-ray 
absorptiometry (DEXA) scan. Participants were measured in 
the hospitals by trained technicians using a total body scan 
protocol prior to start of chemotherapy (n = 86) or during the 
first cycle of chemotherapy (n = 86). Based on the total body 
DEXA-scan body weight (kg), fat mass (kg and relative to 
total body weight), and lean mass (kg and relative to total 
body weight) were assessed. Body composition data were 
included in the models as continuous variables. In addition, 
we categorized patients into tertiles of lean mass, and ter-
tiles of fat mass (Supplementary Tables 2 and 3). Using this 
categorization, we defined the lowest tertile of lean mass as 
“low lean mass,” and the upper two tertiles as “normal lean 
mass;” in addition, the highest tertile of fat mass was defined 
as “high fat mass” and the lower two tertiles as “normal fat 
mass.” Based on this categorization, we created four groups: 
(1) patients with a normal lean mass and normal fat mass, 
(2) patients with a normal lean mass and high fat mass, (3) 
patients with low lean mass and normal fat mass, or (4) 
patients with low lean mass and high fat mass.
Toxicity‑induced modifications of treatment
Information regarding chemotherapy and toxicity was 
abstracted from medical records using a standardized form. 
Treatment information included detailed information on type 
and dose of chemotherapy, number of cycles planned, and 
start dates of each cycle. Furthermore, information on actual 
administered dose, toxicities, and reasons for treatment 
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modifications were collected per cycle. Toxicity-induced 
modifications of treatment were defined as dose reductions, 
cycle delays, or premature termination of chemotherapy 
[16]. Also, if a planned cytotoxic regime was changed to 
another regime because of toxicities, this was reported as 
a treatment modification. If the reason for a dose reduction 
or cycle delay was unknown (n = 4), we included them as 
toxicity-induced modifications of treatment. Logistical or 
other non-medical reasons for cycle delays were not classi-
fied as toxicity-induced modification of treatment.
Patient and clinical characteristics
Information about tumour stage at diagnosis and timing 
of chemotherapy (adjuvant versus neo-adjuvant) was col-
lected from medical records. Information regarding age at 
cancer diagnosis and height was collected using a general 
questionnaire. Based on body weight of the DEXA-scan 
and self-reported height, BMI at diagnosis was calculated. 
Chemotherapy regimens were categorized as combined or 
sequential regimes (Supplementary Table 1); combined 
regimes included schemes with different components admin-
istered together during all cycles, and included TAC, FEC, 
DOC-CYCLO, CDT(P) PT, and CTP. Sequential regimes 
included schemes with different components that were 
administered in different cycles and included AC/P(T), FEC/
DOC, and AC/DOC/(T).
Data analysis
Population characteristics are presented as median with 
interquartile range (IQR) or number with percentage for the 
total study population, and participants experiencing a toxic-
ity-induced modification of treatment (yes vs. no) separately.
Hazard ratios (HRs) and 95% CI were calculated to assess 
the association between body composition and time to treat-
ment modification using a Cox proportional hazard regres-
sion model; time was expressed as the number of completed 
cycles of chemotherapy until there was treatment modifi-
cation. For example, if a patient had 6 planned cycles of 
chemotherapy and did not experience any toxicity-induced 
modification of treatment, time was censored at 6 cycles. 
The proportional hazard assumption was checked and was 
not violated, as evaluated by the goodness-of-fit test using 
Schoenfeld residuals (p > 0.05).
For all analyses, we constructed a separate model for each 
body composition parameter, i.e., BMI (kg/m2), fat mass per 
5%, fat mass per 5 kg, lean mass per 5%, and lean mass per 
5 kg. In addition, we assessed HRs for the following four 
groups: (1) patients with a normal lean mass and normal 
fat mass versus, (2) patients with a normal lean mass and 
high fat mass, (3) patients with low lean mass and normal 
fat mass, or (4) low lean mass and high fat mass. Stratified 
analyses were conducted for patients receiving a sequential 
regime versus a combined regime, and for patients receiving 
adjuvant chemotherapy versus neo-adjuvant chemotherapy. 
A sensitivity analysis was conducted for toxicity-induced 
treatment modifications occurring within the first 6 cycles 
of chemotherapy. This was done to account for the fact that 
patients with a higher number of cycles planned have higher 
odds of experiencing toxicities as they go through more 
cycles. In this sensitivity analysis, only toxicity-induced 
treatment modifications occurring within the first 6 cycles 
were considered.
Analyses were adjusted for age, since older women have 
an increased risk of experiencing toxicities and age is asso-
ciated with specific body composition characteristics [18]. 
Based on literature, BSA was considered as potential covari-
ate, but not included in the analyses since BSA was strongly 
related with the body composition parameters (multicollin-
earity). All analyses were performed using SAS version 9.4 
(SAS Institute, Inc., Cary, NC, USA).
Results
The median age of the 172 women included was 51.8 years 
(Table 1). More than half of the patients were overweight 
or obese at diagnosis. Most patients had a stage II tumour, 
received adjuvant chemotherapy with a sequential regime 
consisting of 6 or less planned cycles. Table 1 shows that 
women experiencing a toxicity-induced modification of 
treatment were more often treated with a sequential regime 
of adjuvant chemotherapy compared to the women not expe-
riencing a treatment modification. In addition, women expe-
riencing a toxicity-induced modification of treatment had a 
higher body weight, were more often overweight or obese, 
had a higher fat mass and lower percentage of lean mass 
compared to the women not experiencing a modification.
Table 2 specifies how often the specific types of treatment 
modifications occurred. During chemotherapy, more than 
half of the patients experienced an adjustment in relative 
dose intensity (95 out of 172 patients, 55%). Of these 95 
patients, 14% (n = 13) stopped prematurely, 53% (n = 50) had 
a dose reduction, and 34% (n = 32) had a cycle delay as their 
first toxicity-induced modification of treatment. In total, 48% 
(n = 57) of the women receiving 6 or less planned cycles 
experienced a toxicity-induced modification versus 72% 
(n = 38) of the women receiving more than 6 planned cycles.
A higher BMI was associated with a higher risk of 
toxicity-induced modifications of treatment (HR 1.06 
per kg/m2 (95% CI 1.02–1.11). Higher absolute fat mass 
was associated with higher risk of modifications [HR per 
5 kg fat mass: 1.14 (95%CI 1.04–1.25)]. Higher relative 
fat mass was also associated with a higher risk of modi-
fications [HR per 5% increase in fat mass: 1.21 (95% CI 
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1.05–1.38)], see Table 3. A higher percentage of relative 
lean mass was associated with a lower risk of toxicity-
induced modification of treatment [HR per 5 percent 
increase in lean mass: 0.83 (95% CI 0.72–0.96)]. Abso-
lute lean mass in kg was not associated with treatment 
modifications (Table 3).
A total of 54 patients had a low lean mass in combina-
tion with high fat mass (Table 4). Having a low lean mass in 
combination with high fat mass was associated with a higher 
risk of toxicity-induced modifications of treatment versus 
having a normal lean mass in combination with normal fat 
mass (HR 1.33, 95% CI 1.01–1.75).
Figure 1 shows the time in cycle numbers until the occur-
rence of the first toxicity-induced modification of treatment. 
In total, 73 of the 95 women (77%) experienced their first 
modification within the first 6 cycles of chemotherapy. 
Table 1  Demographic, clinical, and body composition characteristics of breast cancer patients treated with chemotherapy
Data are given for the total group and stratified by “Toxicity-induced modification of treatment” Yes or No
*Mann-Witney U for continuous variables, χ2 for categorical variables
Total (n = 172) Toxicity-induced modifica-
tion of treatment: yes (n = 95)
Toxicity-induced modifica-
tion of treatment: no (n = 77)
P value*
Demographics
Age, years (median, IQR) 51.8 (46.8; 59.1) 52.1 (47.4; 60.8) 51.5 (46.4; 54.6) 0.16
Medical profile
 Stage (n, %) 0.82
  I 44 (25.6) 26 (27.4) 18 (23.4)
  II 105 (61.1) 57 (60.0) 48 (62.3)
  III 23 (13.4) 12 (12.6) 11 (14.3)
 Chemotherapy (n, %) 0.68
  Adjuvant 111 (64.5) 67 (70.5) 44 (57.1)
  Neo-adjuvant 61 (35.5) 28 (29.5) 33 (42.9)
 Type of chemotherapy (n, %) 0.03
  Combined regime 78 (45.3) 36 (37.9) 42 (54.6)
  Sequential regime 94 (54.7) 59 (62.1) 35 (45.5)
 Number of cycles chemotherapy (n, %) < 0.01
  6 or less 119 (69.2) 57 (60.0) 62 (80.5)
  More than 6 53 (30.8) 38 (40.0) 15 (19.5)
Anthropometry and body composition
 Body weight, kg (median, IQR) 70.5 (63.9; 81.7) 74.1 (64.4; 84.6) 68.2 (63.1; 76.1) 0.04
 Height, cm (median, IQR) 168 (164; 173) 168 (162; 173) 168 (164; 173) 0.30
 Body surface area (BSA), (median, IQR) 1.8 (1.7; 2.0) 1.8 (1.7; 2.0) 1.8 (1.7; 1.9) 0.08
 Body mass index (BMI) kg/m2 (median, IQR) 25.5 (22.5; 29.1) 26.5 (23.9; 29.8) 24.5 (21.7; 27.2) < 0.01
 Fat mass, percentage (median, IQR) 36.7 (31.4; 42.2) 38.6 (33.7; 44.8) 35.0 (29.7; 39.9) < 0.01
 Fat mass, kg (median, IQR) 26.0 (20.2; 34.2) 27.6 (20.8; 36.3) 23.1 (18.4; 31.1) 0.01
 Lean mass, percentage (median, IQR) 60.2 (33.2; 65.1) 58.5 (53.1; 63.5) 61.8 (57.2; 66.7) < 0.01
 Lean mass, kg (median, IQR) 43.1 (29.4; 46.8) 43.1 (39.5; 47.5) 42.8 (39.3; 46.6) 0.76
 Appendicular skeletal mass, kg (median, IQR) 18.2 (16.8; 20.2) 18.2 (16.6; 20.2) 18.2 (16.9; 20.1) 0.83
 Skeletal muscle index, kg/m2 (median, IQR) 6.5 (6.0; 7.2) 6.5 (6.0; 7.3) 6.4 (6.; 7.1) 0.56
Table 2  Distribution of the 
three types of treatment 
modifications as experienced 
by breast cancer patients in 
the COBRA study among 
patients who had no more than 
6 planned chemotherapy cycles 
versus more than 6 cycles
Toxicity All patients (n = 172) 6 planned cycles or 
less (n = 119)
More than 6 
planned cycles 
(n = 53)
Any modification, n (%) 95 (55.2) 57 (47.9) 38 (71.7)
Cycle delay 32 (33.7) 17 (29.8) 15 (39.5)
Dose reduction 50 (52.6) 36 (63.2) 14 (36.8)
Premature termination 13 (13.7) 4 (7.0) 9 (23.7)
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Sensitivity analyses including only modifications occurring 
within the first 6 cycles showed similar results compared 
to the analysis in which we included modifications in all 
cycles (Table 3).
Stratified results did not suggest that the associations 
between body composition and toxicity-induced modi-
fications of treatment were different for combined versus 
sequential regimes, nor for neo-adjuvant versus adjuvant 
chemotherapy (data not shown). We had insufficient power 
to stratify by specific chemotherapy regimens, but none of 
the regimens appeared more related to toxicity profiles than 
others (Supplementary Table 1).
Discussion
This study showed that a higher absolute or relative fat mass 
and a lower percentage of lean mass were associated with an 
increased risk of toxicity-induced modifications of treatment 
in stage I-IIIB breast cancer patients treated with chemo-
therapy, while absolute lean mass in kg was not associated 
with these modifications. Our results suggest that fat mass 
Table 3  Association between body composition parameters and risk 
of toxicity-induced modifications of treatment in early stage breast 
cancer patients
HRs were adjusted for age
Bold values are statistically significant
Variable Total/cases HR 95% CI
All patients
 BMI per kg/m2 172/95 1.06 1.02; 1.11
 Fat mass per 5% 172/95 1.21 1.05; 1.38
 Fat mass per 5 kg 172/95 1.14 1.04; 1.25
 Lean mass per 5% 172/95 0.83 0.72; 0.96
 Lean mass per 5 kg 172/95 1.07 0.92; 1.27
 Appendicular skeletal mass per kg 172/95 1.01 0.95; 1.08
 Skeletal muscle index per kg/m2 172/95 1.07 0.87; 1.32
Sensitivity analysis: modifications in the first 6 cycles
 BMI per kg/m2 172/73 1.06 1.01; 1.11
 Fat mass per 5% 172/73 1.18 1.01; 1.37
 Fat mass per 5 kg 172/73 1.13 1.02; 1.25
 Lean mass per 5% 172/73 0.85 0.72; 1.00
 Lean mass per 5 kg 172/73 1.08 0.91; 1.30
 Appendicular skeletal mass per kg 172/73 1.02 0.95; 1.09
 Skeletal muscle index per kg/m2 172/73 1.10 0.88; 1.38
Table 4  Categorization of 
patients into body composition 
groups and association of body 
composition groups with risk of 
toxicity-induced modifications 
of treatment in early stage breast 
cancer patients
Categorization is based on tertiles with “normal lean mass” defined as the upper two tertiles of lean mass, 
“normal fat mass” as the lowest two tertiles of fat mass, “low lean mass” as the lowest tertile of lean mass 
and “high fat mass” as the upper tertile of fat mass
*Not included in Cox Proportional hazard analysis, because of low numbers. HR adjusted for age
Group Total Toxicity-induced modifi-
cation of treatment: yes
Toxicity-induced modifi-
cation of treatment: no
HR
Normal lean and normal fat 111 55 56 Ref
Normal lean and high fat* 4 2 2 –
Low lean and normal fat* 3 1 2 –
Low lean and high fat 54 37 17 1.33 
(1.01, 
1.75)
Fig. 1  Cycle number in which 
the first toxicity-induced modi-
fication of treatment occurred, 
stratified for patients receiving a 
chemotherapy regime consisting 
of 6 or less planned cycles and 
patients receiving a chemother-
apy regime consisting of more 
than 6 planned cycles
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strongly determines the risk of treatment modifications dur-
ing chemotherapy in breast cancer patients.
Two earlier studies [14, 15] stressed the importance 
of total lean mass in the association with chemotherapy-
induced toxicities. However, those studies did not assess 
chemotherapy-induced toxicities in association with rela-
tive lean mass or total fat mass (kg or percentage). The first 
study (n = 151) used CT-scans to assess body composition 
and concluded that lower total lean mass and skeletal muscle 
gauge—a composite endpoint of muscle mass and muscle 
radio density—were associated with increased risk of treat-
ment-related grade 3–4 toxicities in patients receiving dox-
orubicin-cyclophosphamide (AC)-taxane-based cytotoxic 
regimens [14]. The second study (n = 24) concluded that a 
lower total lean mass was associated with higher incidence 
of dose-limiting toxicities during the first cycle of FEC100 
[15], again with CT-scan as measurement of body composi-
tion. Both studies extrapolated total lean mass from skeletal 
muscle cross-sectional area of a CT-scan at the level of the 
third vertebrae, but did not report results of toxicity associa-
tions with percentage of total lean mass or fat mass. Moreo-
ver, the study populations of both studies differed from our 
population, making it challenging to compare the results. For 
example, in the study of Prado 22 out of 24 patients expe-
rienced an adjustment in relative dose during the first cycle 
of chemotherapy [15], which is considerably more than our 
study where 15 out of 172 patients experienced a toxicity-
induced modification of treatment after the first cycle. This 
suggests that the selection process of participants eligible for 
their study led to a group of patients at high risk of toxicities 
which may impact the generalizability of those findings. In 
the study by Shachar et al, the average BMI was 2–3 kg/m2 
higher than in our study, while lean mass was slightly lower 
[14]. Thus, it is plausible that fat mass was higher in that 
study, and that patients with lower lean, and/or higher fat 
mass experienced the highest risk of toxicities, in line with 
the results of our current study. Yet, baseline differences in 
body composition between studies plus different outcome 
measures to assess toxicities obstruct direct comparison 
between studies. We could not differentiate between visceral 
and subcutaneous abdominal adiposity with our DEXA data. 
New algorithms are emerging that enable this distinction, 
which opens up avenues for further study [19].
Possible mechanisms for the observed association between 
body composition and toxicity-induced modifications of treat-
ment are unclear, but could be either biological or clinical. 
Depending on the type of cytotoxic agent, drugs may be more 
hydrophilic or hydrophobic which will affect the clearance and 
volume of distribution of the drugs. For hydrophilic drugs, it 
has been hypothesized that patients with a relatively lower 
lean mass may be overdosed when using body surface area to 
calculate dosage, and may present with higher rates of toxic-
ity-induced modifications of treatment. In our study, stratified 
results based on type of chemotherapy did not suggest that 
associations between body composition and toxicity-induced 
modifications of treatment were different for combined versus 
sequential regimes, but we did not have sufficient statistical 
power for further stratifications.
A more clinical, although speculative, explanation for a 
higher risk of toxicities in patients with low lean mass could 
be that clinicians treat patient with a lower percentage of 
lean mass differently than patients with a higher percentage 
lean mass, although lean mass is seldom formally assessed 
in clinical practice. Nevertheless, patients with a low lean 
mass may be frailer, and may generally experience other 
comorbidities, which could prompt the medical oncologist 
to adapt the chemotherapy protocol earlier than patients with 
a better physical condition.
In conclusion, a higher BMI and a higher fat mass (kg 
and percentage) are associated with an increased risk of 
toxicity-induced modifications of treatment, while absolute 
lean mass was not associated with risk of these modifica-
tions. This suggests that total fat mass strongly determines 
the risk of toxicity-induced modifications of treatment dur-
ing chemotherapy in breast cancer patients. These findings 
highlight the importance of fat mass in relation to toxicities 
and provide unique leads for further clinical studies focus-
sing on implementation of body composition measures dur-
ing planning of chemotherapy.
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